Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 2,515 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Stroke
Interventions: rehabilitation robotics, Movement therapy; Device · Procedure
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 21 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Hypothermia
Interventions: Nasopharyngeal; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Neoplasms
Interventions: Pimasertib Capsule (Part A), Pimasertib Tablet (Part A), Pimasertib Capsule (Part B and trial extension phase); Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Healthy
Interventions: ARV-471, Rosuvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Lactose Intolerants, Lactose Malabsorption, Caseins
Interventions: A1/A2 milk with oral naloxone, A1PF milk with oral naloxone; Other
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Acute Respiratory Failure
Interventions: Rapid sequence intubation: sedative first, Rapid sequence intubation: paralytic first; Other
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cerebellar Disease, Dementia, Healthy, Parkinson's Disease
Interventions: Cadwell Rapid Rate Magnetic Stimulator; Device
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride, Tolbutamide, Omeprazole, Relacorilant; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Lung Cancer
Interventions: comparative genomic hybridization, gene expression microarray analysis, proteomic profiling analysis, biologic sample preservation procedure, nasal brushing, Blood draw, Urine collection, sputum sample, fluorescence bronchoscopy with airway biopsy, fine needle aspiration of the lung, thoracentesis; Genetic · Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2027
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Healthy
Interventions: Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC), Canagliflozin, Metformin IR; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Neoplasms, Breast
Interventions: lapatinib, Digoxin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Epilepsy
Interventions: Investigational Medicinal Product (MR1), Investigational Medicinal Product (MR2), Investigational Medicinal Product (MR3), Investigational Medicinal Product (MR4), Investigational Medicinal Product (MR5), Investigational Medicinal Product (IR); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gout, Hyperuricemia
Interventions: Xanthine Oxidase Inhibitor, nonsteroidal anti-inflammatory drug; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Astigmatism
Interventions: 1-DAY ACUVUE® MOIST contact lenses, 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses, No contact lenses; Device · Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 39 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Lu AG06466, Itraconazole; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: SKL24741, Placebo; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Healthy
Interventions: Tirzepatide, Single Dose Pen, Multi-use Prefilled Pen; Drug · Device
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: South Miami, Florida • San Antonio, Texas • Salt Lake City, Utah

Conditions: Healthy
Interventions: Macitentan 10 mg, Tadalafil 20 mg, Macitentan 10 mg/Tadalafil 20mg FDC; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Normal Volunteers
Interventions: Not listed
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Duarte, California

Conditions: Obesity, Childhood, Parenting
Interventions: Obesity Prevention Group, Obesity Prevention Group + Food Boxes, Infant Safety and Injury Prevention Group; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 0 Years to 90 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Austin, Texas

Conditions: Metastatic Cancer
Interventions: Genetically Informed Therapy; Genetic
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: SLC6A1
Interventions: AAV9.SLC6A1 Gene Therapy; Biological
Lead sponsor: Emily de los Reyes; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy, Drug Drug Interaction
Interventions: Itraconazole, Rifampin, KBP-5074; Drug
Lead sponsor: KBP Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Springfield, Missouri

Search by objective public record fields.

Shoulder, or Elbow, or Wrist: What Should we Train First After a Stroke?

Optimal Positioning of Nasopharyngeal Temperature Probes: A Prospective Cohort Study

Relative Bioavailability of Pimasertib in Cancer Patients

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

Milk Beta Caseins on Digestive Discomfort, Gastric Emptying

Drug Order for Rapid Sequence Intubation

Effects of Brain Stimulation on Learning and Reasoning

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer

Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.

The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults

Evaluating and Improving Functional Driving Vision of Patients With Astigmatism

Bioequivalency Study of Zidovudine Under Fasting Conditions

Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects

A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices

A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants

Optimization of Novel DCE-MRI Imaging Sequences for Cancer Therapy Monitoring

Mothers And careGivers Investing in Children

Genetically-informed Therapies for Patients With Metastatic Cancer

Gene Therapy for SLC6A1 Neurodevelopmental Disorder

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects